Why has the Risk-Monger joined the tobacco harm reduction fight? Like glyphosate, it is about proper risk management.
Category: SlimeGate
SlimeGate 3.2.3.4: Retract the Smith et al. (2016) paper: “Key Characteristics of Carcinogens…”
If papers are retracted because of industry interest, why aren’t papers written for the litigation industry retracted?
SlimeGate 3.2.3.3: The Litigation Industry’s Influence on IARC’s Talc Monograph
Part 3 of the SlimeGate talc exposé shows how IARC was working in service to the US litigation industry.
SlimeGate 3.2.3.2: Covering up Dissent on IARC’s 3rd Talc Monograph
IARC’s 3rd talc monograph did not reflect the experts’ dissent. Instead they covered it up to project a consensus.
SlimeGate 3.2.3.1 – IARC’s Talc Journey Part 1: A Tale of Three Talcs
This exposé on IARC’s three talc monographs shows an agency willing to change their methodology to meet their political objectives.
SlimeGate 3.1.2.2: Five Reasons Why the Ramazzini Institute Fired their Director
The Sudden Departure of Daniele Mandrioli Indicates an Activist Science Group in Disarray
SlimeGate 3.2.2: IARC’s Attack on Atrazine
IARC is up to their old tricks again. We are starting to learn to ignore them.
SlimeGate 2.3.4: The Litigation Finance Whistleblower Exposé Part 2
Litigation finance ethical challenges are made worse when we see how big external investors are pulling the strings and taking most of the payouts.
SlimeGate 2.3.3: The Litigation Finance Whistleblower Exposé Part 1
I interviewed a former litigation finance analyst willing to blow the whistle on the corrupt industry.
SlimeGate 3.4.1: The Paraquat Playbook and Bad Activist Science
Shapeshifter, Contortionist and Cherry-Picker: What a US judge has to say about Marty Wells
Glyphysteria: The Mob has a New Public Enemy #1
There’s a new Public Enemy #1 to channel activist rage on glyphosate
My Experience with a Health Journalist on Aspartame
A news reporter contacted the Risk-Monger. It didn’t go as planned.
The Risk-Monger 